DOCSLIB.ORG

List of Registred Drugs in Armenia (01.03.2017-31.03.2017)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
List of Registred Drugs in Armenia (01.03.2017-31.03.2017) LIST OF REGISTRED DRUGS IN ARMENIA (01.03.2017-31.03.2017) International nonproprietary name Dose and Registration Term of Legal Status N Trade name Drug form Manufacturer Country ATC1 code License holder (generic) or active packaging number registration for Supply ingredients name Eli Lilly Regional Lilly France S.A.S., Operations GmbH., solution for 100IU/ml, Zone Industrielle, 2 17.03.2017 1 Abasaglar insulin glargine France A10AE04 16535 PoM2 Koelblgasse 8-10, injection 3ml cartridges (5) rue du Colonel Lilly, 17.03.2022 1030, Vienna, 67640 Fegersheim Austria Olainfarm JSC, 5 300mg, Olainfarm JSC, 5 06.03.2017 Rupnicu Str., 2 Adaptol mebicar capsules hard in blister (20/2x10/, Rupnicu Str., Olaine, Latvia N06BX21 16440 PoM 06.03.2022 Olaine, LV-2114, 30/3x10/, 40/4x10/) LV-2114 Latvia Olainfarm JSC, 5 Olainfarm JSC, 5 500mg, 06.03.2017 Rupnicu Str., 3 Adaptol mebicar tablets Rupnicu Str., Olaine, Latvia N06BX21 16441 PoM in blister (20/2x10/) 06.03.2022 Olaine, LV-2114, LV-2114 Latvia 10mg, Pharmstandard- OTCPharm PJSC, fabomotizole in blisters Leksredstva JSC, 27.03.2017 123317, Moscow, 4 Afobazol (fabomotizole tablets (30/1x30/, 60/3x20/, 305022, Kursk, Russia N05BX04 14729/2 PoM 30.07.2020 Testovskaya str., 10, dihydrochloride) 60/2x30/, 90/3x30/, Agregatnaya 2nd str., Russia 120/4x30/) 1a/18 Gedeon Richter 15mg/g, Gedeon Richter PLC, 17.03.2017 PLC, Gyomroi ut 5 Airtal aceclofenac cream 60g aluminium Gyomroi ut 19-21, Hungary M01AB16 16514 OTC3 17.03.2022 19-21, 1103 tube 1103 Budapest Budapest, Hungary 1 Gedeon Richter PLC, Gyomroi ut 19-21, 1103 Budapest - batch releaser, Industrias Gedeon Richter Farmaceuticas powder for oral 100mg, 17.03.2017 PLC, Gyomroi ut 6 Airtal aceclofenac Almirall S.L., Ctra. Hungary M01AB16 16515 PoM suspension 3g sachet (20) 17.03.2022 19-21, 1103 Nacional II, Km. 593, Budapest, Hungary Sant Andreu de la Barca, Barcelona, 08740, Spain-bulk manufacturer, packager BIOPHARMA BIOPHARMA PLASMA LLC, 37, solution for 100mg/ml, PLASMA LLC, 9M. 27.03.2017 Kyivska St., Bila 7 Albumin-Biopharma human albumin Ukraine B05AA01 11989/1 PoM infusion 50ml glass bottle: Amosova St, Kyiv, 07.12.2017 Tserkva, Kyiv 03680 region, 09100, Ukraine BIOPHARMA BIOPHARMA PLASMA LLC, 37, solution for 100mg/ml, PLASMA LLC, 9M. 27.03.2017 Kyivska St., Bila 8 Albumin-Biopharma human albumin Ukraine B05AA01 11990/1 PoM infusion 100ml glass bottle: Amosova St, Kyiv, 07.12.2017 Tserkva, Kyiv 03680 region, 09100, Ukraine BIOPHARMA BIOPHARMA PLASMA LLC, 37, solution for 200mg/ml, PLASMA LLC, 9M. 27.03.2017 Kyivska St., Bila 9 Albumin-Biopharma human albumin Ukraine B05AA01 11991/1 PoM infusion 50ml glass bottle Amosova St, Kyiv, 07.12.2017 Tserkva, Kyiv 03680 region, 09100, Ukraine BIOPHARMA BIOPHARMA PLASMA LLC, 37, solution for 200mg/ml, PLASMA LLC, 9M. 27.03.2017 Kyivska St., Bila 10 Albumin-Biopharma human albumin Ukraine B05AA01 11992/1 PoM infusion 100ml glass bottle Amosova St, Kyiv, 07.12.2017 Tserkva, Kyiv 03680 region, 09100, Ukraine 2 S.C.Biotehnos S.A., Str. Gorunului nr. 3- 5, Otopeni, Jud. Ilfov, 075100- batch releaser, secondary S.C.Biotehnos S.A., 0,1ml/ml, packager, S.C. Str. Gorunului nr. 3- bioactive concentrate solution for 06.03.2017 11 Alflutop 2ml ampoules, Zentiva S.A., Romania M09AX02 16453 PoM 5, Otopeni, Jud. from small sea fish injection 06.03.2022 in blister (5/1x5/) Theodor Pallady Blvd Ilfov, 075100, nr. 50, sector 3, Romania 032266 Bucharest, Romania- bulk manufacturer, primary packager S.C.Biotehnos S.A., Str. Gorunului nr. 3- 5, Otopeni, Jud. Ilfov, 075100- batch releaser, secondary S.C.Biotehnos S.A., 0,1ml/ml, packager, S.C. Str. Gorunului nr. 3- bioactive concentrate solution for 06.03.2017 12 Alflutop 1ml ampoules, Zentiva S.A., Romania M09AX02 16454 PoM 5, Otopeni, Jud. from small sea fish injection 06.03.2022 in blister (10/2x5/) Theodor Pallady Blvd Ilfov, 075100, nr. 50, sector 3, Romania 032266 Bucharest, Romania- bulk manufacturer, primary packager SIC SIC "Borshchahivskiy "Borshchahivskiy Chemical- Chemical- ambroxol (ambroxol 30mg, 01.03.2017 13 Ambroxol hydrochloride tablets Pharmaceutical Ukraine R05CB06 16483 OTC Pharmaceutical hydrochloride) in blister (20/2x10/) 01.03.2022 Plant" PJSC, 17, Mira Plant" PJSC, 17, St, Kyiv, 03134 Mira St, Kyiv, 03134, Ukraine 3 DL-methionine, L- leucine, L-valine, L- isoleucine, L-threonine, 9,2mg+9,15mg+ L-tryptophan, L- 5mg+5mg+5mg+ GL Corporation, phenylalanine, L-lysine 5mg+5mg+25mg+ Hankook Korus Woori Venture (L-lysine 1000IU+100IU+ Pharm Co., Ltd, 30, Tower 201, 70, hydrochloride), vitamin 10mg+2,5mg+ 06.03.2017 14 Amivit-Asteria capsules Gangjeo-ro, Jecheon- Korea South A11JC 16435 OTC Seonyu-ro, A, vitamin D2, vitamin 1,5mg+10mg+ 06.03.2022 Si, Chungcheongbuk- YoungDeungPo- E, vitamin B1, vitamin 5mg+2.5mg+ do Ku, Seoul, South B2, vitamin B3, vitamin 0,5mcg+100mcg+ Korea B6, calcium 25mg, pantothenate, vitamin in blister (30/3x10/) B12, folic acid, vitamin C Pharmaceutical 10mg, Pharmaceutical Company in blister (50/1x50/, Company "Zdorovye" propranolol (propranolol 17.03.2017 "Zdorovye" LLC, 15 Anaprilin-Zdorovye tablets 50/5x10/), LLC, 61013, Ukraine C07AA05 16516 PoM hydrochloride) 17.03.2022 61013, Kharkov, in plastic container Kharkov, Shevchenko str., 22, (50) Shevchenko str., 22 Ukraine Pharmaceutical 40mg, Pharmaceutical Company in blister (50/1x50/, Company "Zdorovye" propranolol (propranolol 17.03.2017 "Zdorovye" LLC, 16 Anaprilin-Zdorovye tablets 50/5x10/), LLC, 61013, Ukraine C07AA05 16517 PoM hydrochloride) 17.03.2022 61013, Kharkov, in plastic container Kharkov, Shevchenko str., 22, (50) Shevchenko str., 22 Ukraine Remedica Ltd, Remedica Ltd, 1mg, Aharnon street, Aharnon street, 13.03.2017 17 Aremed anastrozole tablets film-coated in blisters Cyprus L02BG03 14684/1 PoM Limassol Industrial Limassol Industrial 29.06.2020 (28/2x14/) Estate, 3056 Estate, 3056 Limassol Limassol, Cyprus l'Alleud GlaxoSmithKline hydroxyzine UCB Pharma S.A., Export Ltd., 980 25mg, 13.03.2017 18 Atarax (hydroxyzine tablets film-coated Chemin du Foriest, B- Belgium N05BB01 15024/1 PoM Great West Road, in blister (25/1x25/) 02.12.2020 hyrochloride) 1420 Braine Brentford, Middlesex, TW8 9GS, UK 4 Boehringer fenoterol (fenoterol Ingelheim Istituto de Angeli hydrobromide), 500mcg/ml+ International S.R.L. Loc. Prulli, 06.03.2017 19 Berodual ipratropium bromide solution inhalation 261mcg/ml, Italy R03AL01 16436 PoM GmbH, Binger 103/C 50066 06.03.2022 (ipratropium bromide 20ml glass container Strasse 173, 55216 Reggello, Firenze monohydrate) Ingelheim am Rhein, Germany Boehringer Boehringer Ingelheim Ingelheim Pharma 100mcg/dose, International fenoterol (fenoterol aerosol for GmbH & Co. KG, 31.03.2017 20 Berotec N 10ml aluminium Germany R03AC04 12208/1 PoM GmbH, Binger hydrobromide) inhalation Binger Strasse 173, D- 07.03.2018 bottle Strasse 173, 55216 55216 Ingelheim am Ingelheim am Rhein Rhein, Germany Alkaloid AD Alkaloid AD Skopje, Skopje, Blvd. ibuprofen (ibuprofen 200mg, Blvd. Aleksandar 06.03.2017 21 Caffetin Lady tablets film-coated Macedonia M01AE01 16458 OTC Aleksandar lysinate) in blister (10/1x10/) Makedonski 12, 1000 06.03.2022 Makedonski 12, Skopje 1000 Skopje Veyx-Pharma GmbH, Sohreweg 6, 34639 Schwarzenborn- calcium gluconate batch releaser, Veyx-Pharma (calcium gluconate 380mg/ml+ secondary packager, GmbH, Sohreweg monohydrate), solution for 60mg/ml+50mg/ml, QA12; 17.03.2017 22 Calciveyxol 38 Bela-Pharma GmbH Germany 16512 PoM 6, 34639 magnesium chloride infusion 500ml plastic bottle veterinary drug 17.03.2022 & Co.KG, Lohner Str. Schwarzenborn, (magnesium chloride (1, 12) 19, Vechta, Germany hexahydrate), boric acid Niedersachsen, 49377, Germany- bulk manufacturer, primary packager 5 Borisov Medical Borisov Medical Preparations Plant Preparations Plant 1000mg, OJSC, 64/27, cefazolin (cefazolin powder for solution OJSC, 64/27, 13.03.2017 23 Cefazolin glass vial (1, 10, Belarus J01DB04 11972/1 PoM Chapayev str., sodium) for injection Chapayev str., 19.11.2017 270) Borisov 222120, Borisov 222120, Minsk oblast, Minsk oblast Belarus Sopharma JSC, str. Sopharma JSC, str. 25mg, 17.03.2017 24 Cinnarizine Sopharma cinnarizine tablets Iliensko shosse 16, Bulgaria N07CA02 16513 PoM Iliensko shosse 16, in blister (50/1x50/) 17.03.2022 1220 Sofia 1220 Sofia, Bulgaria "Sotex"PharmFirm" "Sotex"PharmFirm" CJSC, Bld. 10, 11, 12, CJSC, Bld. 11, village Belikovo, village Belikovo, 250mg/ml, rural settlement rural settlement citicoline (citicoline solution for i/v and 06.03.2017 25 CITOLEPT 4ml ampoules, Bereznjakovskoe, Russia N06BX06 16449 PoM Bereznjakovskoe, sodium) i/m injection 06.03.2022 in blister (5/1x5/) Sergiev-Posad Sergiev-Posad municipal district, municipal district, Moscow Region, Moscow Region, 141345 141345, Russia "Sotex"PharmFirm" "Sotex"PharmFirm" CJSC, Bld. 10, 11, 12, CJSC, Bld. 11, village Belikovo, village Belikovo, 125mg/ml, rural settlement rural settlement citicoline (citicoline solution for i/v and 06.03.2017 26 CITOLEPT 4ml ampoules, Bereznjakovskoe, Russia N06BX06 16450 PoM Bereznjakovskoe, sodium) i/m injection 06.03.2022 in blister (5/1x5/) Sergiev-Posad Sergiev-Posad municipal district, municipal district, Moscow Region, Moscow Region, 141345 141345, Russia 6 Medac GmbH, Theaterstrasse 6, 22880 Wedel - secondary packager, batch releaser Medac GmbH, powder for solution 200mg, (Oncotec Pharma 31.03.2017 Theaterstrasse 6, 27 Dacarbazine medac dacarbazine for injection or Germany L01AX04 13771/2 PoM glass vial (10) Production GmbH, 05.09.2019 22880 Wedel, infusion Am Pharmapark, Germany 06861 Dessau- Rosslau, Germany - bulk
Load more

Recommended publications
  • Energy Efficiency And
    Progress with The Energy Policy Review: A Perspective OIES Seminars 7 October 2003 John Bower Overview What the White Paper Said Reality Dawns An alternative 20:20 Vision John Bower Progress on UK Energy White Paper 2 What the White Paper Said UKEWP refocused energy policy away from a UK driven liberalisation agenda… GOALS AND POLICIES 1. Reduce CO2 emissions by 60% by 2050 Reduce amount of energy we consume Central to future market and policy will be emissions trading Raise efficiency standards in home appliances and housing Encourage low carbon fuels and renewables through grants and subsidy 2. Maintain reliability of energy supplies Right infrastructure / regulatory systems in UK and liberalisation of Europe Pursue regional stability and economic reform in producing areas Promote understanding of markets and conditions for FDI in producing areas Forward prices will signal the need for investment Improve contingency planning in dealing with major incidents John Bower Progress on UK Energy White Paper 3 What the White Paper Said …. towards an EU driven multifaceted agenda GOALS AND POLICIES 3. Promote competitive markets in UK and beyond Raise rate of sustainable economic growth Support business and competitiveness through reliable / affordable energy Encourage firms to innovate, reduce cost, deliver better goods and services Use market based instruments to deliver policy goals Work with business to prepare them for the low carbon economy of the future 4. Ensure that every home is adequately and affordably heated Reduce poverty by lowering prices and raising social security payments Improve quality of housing stock via insulation and energy efficiency grants John Bower Progress on UK Energy White Paper 4 What the White Paper Said UKEWP relied on carbon trading and uneconomic/unproven technology… ENERGY SYSTEM IN 2020 1.
    [Show full text]
  • MI4A Vaccine Purchase Data for Countries This Note Is Intended to Guide Countries in Their Use of the MI4A Vaccine Purchase Data
    MI4A Vaccine Purchase Data for Countries This note is intended to guide countries in their use of the MI4A vaccine purchase data. What data is available? new vaccine introductions, but also for product switches – and to understand the status of product The WHO vaccine market intelligence database registrations. Fifty-six Member States responded compiles vaccine purchase (product, price and to these new questions. procurement) data as reported by countries via the WHO/UNICEF Joint Reporting Form (JRF) over the This information is essential to WHO’s efforts to period of 2013–2018. While country names are not improve global market forecasts and inform displayed, data is publicly available on the MI4A suppliers’ and global policy-makers’ investment website and provides information by country decisions. WHO encourages all countries to characteristics (e.g. region, income group…) by report information on new introduction plans and vaccine and by year of purchase, along with price planned product changes as well as to respond to per dose (USD), procurement mechanism and questions related to registration. annual volumes. 1 The number of countries reporting vaccine How can my country use this data? purchase data through the JRF continues to Countries can use the vaccine purchase data in increase year after year, with 182 Member States several different ways, such as to: (93%) reporting some vaccine procurement information in 2019 – including 158 (81%) fully • Understand how the price of vaccines in their reporting on vaccine purchase data. Price reporting immunization schedule relate to other this year marks a 3% increase from last year and products on the market, or compare the more than triple the reporting from 2016.
    [Show full text]
  • The Effect of the Roots of Empathy Program on the Use of Psychotropic Medications Among Youth in Manitoba
    The effect of the Roots of Empathy program on the use of psychotropic medications among youth in Manitoba by Lindsey Dahl A Thesis submitted to the Faculty of Graduate Studies of The University of Manitoba in partial fulfilment of the requirements of the degree of MASTER OF SCIENCE Department of Community Health Sciences, Rady Faculty of Health Sciences, Max Rady College of Medicine University of Manitoba Winnipeg Copyright © 2017 by Lindsey Dahl Abstract Background: Psychotropic medications prescriptions to youth have increased. Roots of Empathy (ROE) is a social and emotional learning program that may influence the use of psychotropic medication. Methods: Administrative data was analyzed in a matched sample of children who received ROE during 2002/03 to 2012/13. Kaplan-Meier survival curves and Cox proportional hazard models were used to estimate the association between ROE and psychotropic medication dispensations. Results: Few significant differences were observed. Children who received ROE in kindergarten to grade 3 had a lower adjusted hazard for an anxiolytic dispensation. Children who received ROE in grade 7 to 8 had a higher hazard for an antipsychotic dispensation. Males who received the program had an increased hazard for an antipsychotic dispensation. Conclusion: There was no consistent differences in the likelihood of being dispensed a psychotropic medication between children who received ROE and children who did not in Manitoba. ii Acknowledgments I would like to first thank my thesis advisor Dr. Randy Fransoo of the Department of Community Health Sciences, Rady Faculty of Health Sciences, Max Rady College of Medicine at the University of Manitoba. Right from our initial meeting, Dr.
    [Show full text]
  • Contribution of Podoviridae and Myoviridae Bacteriophages
    www.nature.com/scientificreports OPEN Contribution of Podoviridae and Myoviridae bacteriophages to the efectiveness of anti‑staphylococcal therapeutic cocktails Maria Kornienko1*, Nikita Kuptsov1, Roman Gorodnichev1, Dmitry Bespiatykh1, Andrei Guliaev1, Maria Letarova2, Eugene Kulikov2, Vladimir Veselovsky1, Maya Malakhova1, Andrey Letarov2, Elena Ilina1 & Egor Shitikov1 Bacteriophage therapy is considered one of the most promising therapeutic approaches against multi‑drug resistant bacterial infections. Infections caused by Staphylococcus aureus are very efciently controlled with therapeutic bacteriophage cocktails, containing a number of individual phages infecting a majority of known pathogenic S. aureus strains. We assessed the contribution of individual bacteriophages comprising a therapeutic bacteriophage cocktail against S. aureus in order to optimize its composition. Two lytic bacteriophages vB_SauM‑515A1 (Myoviridae) and vB_SauP‑ 436A (Podoviridae) were isolated from the commercial therapeutic cocktail produced by Microgen (Russia). Host ranges of the phages were established on the panel of 75 S. aureus strains. Phage vB_ SauM‑515A1 lysed 85.3% and vB_SauP‑436A lysed 68.0% of the strains, however, vB_SauP‑436A was active against four strains resistant to vB_SauM‑515A1, as well as to the therapeutic cocktail per se. Suboptimal results of the therapeutic cocktail application were due to extremely low vB_SauP‑436A1 content in this composition. Optimization of the phage titers led to an increase in overall cocktail efciency. Thus, one of the efective ways to optimize the phage cocktails design was demonstrated and realized by using bacteriophages of diferent families and lytic spectra. Te wide spread of multidrug-resistant (MDR) bacterial pathogens is recognized by the World Health Organi- zation (WHO) as a global threat to modern healthcare1.
    [Show full text]
  • Annex 2 Composition of Oral and Injectable Estrogen–Progestogen Contraceptives
    ANNEX 2 COMPOSITION OF ORAL AND INJECTABLE ESTROGEN–PROGESTOGEN CONTRACEPTIVES Annex 2 lists the composition of brands of estrogen–progestogen preparations used in combined injectables (Table 1), combined oral (Table 2) and phasic oral (Table 3) contraceptives. The countries in which these formulations are used are noted. Are listed only those brands for which availability was reported. The source of these tables is the International Planned Parenthood Foundation (IPPF). Data have been taken from the IPPF 2002 website [http://contraceptive.ippf.org] at the time of the monograph meeting (June 2005). This online site is regularly updated. Table 1. Combined injectables Brand name Composition Countries of availability Acefil Dihydroxyprogesterone acetophenide 150 mg Paraguay + estradiol enanthate 10 mg Agurin Dihydroxyprogesterone acetophenide 150 mg Chile + estradiol enanthate 10 mg Anafertin Dihydroxyprogesterone acetophenide 75 mg El Salvador, Mexico + estradiol enanthate 5 mg Ciclofem Medroxyprogesterone acetate 25 mg Guatemala + estradiol cypionate 5 mg Ciclofemina Medroxyprogesterone acetate 25 mg El Salvador + estradiol cypionate 5 mg Ciclomes Dihydroxyprogesterone acetophenide 150 mg Paraguay + estradiol enanthate 10 mg Ciclovular Dihydroxyprogesterone acetophenide 150 mg Brazil + estradiol enanthate 10 mg Clinomin Dihydroxyprogesterone acetophenide 150 mg Paraguay + estradiol enanthate 10 mg Cyclofem Medroxyprogesterone acetate 25 mg Chile, Indonesia, Malaysia, Mexico, + estradiol cypionate 5 mg Panama, Zimbabwe Cyclofemina Medroxyprogesterone
    [Show full text]
  • Vaccine Purchase Data and Cover Note for Countries
    MI4A Vaccine Purchase Data for Countries The MI4A Vaccine Purchase How can my country use this data?1 Database What data is available? • • • • WORKING DOCUMENT - MI4A Vaccine Purchase Data Note [December 2020] | 1 Immunization Agenda IA 2030 Reporting Vaccine Purchase Data Documenting use of MI4A data WORKING DOCUMENT - MI4A Vaccine Purchase Data Note [December 2020] | 2 Key messages to countries • • • 7 WORKING DOCUMENT - MI4A Vaccine Purchase Data Note [December 2020] | 3 • • • • • . / WORKING DOCUMENT - MI4A Vaccine Purchase Data Note [December 2020] | 4 • • • • • • • 12 WORKING DOCUMENT - MI4A Vaccine Purchase Data Note [December 2020] | 5 • • • • • • • • 13 WORKING DOCUMENT - MI4A Vaccine Purchase Data Note [December 2020] | 6 • • • • • WORKING DOCUMENT - MI4A Vaccine Purchase Data Note [December 2020] | 7 What is MI4A? • • • WORKING DOCUMENT - MI4A Vaccine Purchase Data Note [December 2020] | 8 A. Available Products List - as known to WHO The MI4A Products List provides a snapshot overview of vaccine products available for procurement – irrespective of their WHO prequalification status – as of November 2020. This list reflects information reported by countries through the 2020 Joint Reporting Form (JRF) and is supplemented with available information gathered through separate consultations. As part of the MI4A project, WHO conducts in-depth global market studies where the list of available vaccines can be considered comprehensive and up to date. Studies conducted so far include BCG, D&T-containing, measles-containing, meningococcal, HPV, pneumococcal, rabies, and typhoid vaccines. For all the other vaccines it should be noted that this list may not be complete and may be missing some products whose availability is not documented through public reported data and sources.
    [Show full text]
  • Biotechnology in Russia: Why Is It Not a Success Story?
    Biotechnology in Russia: Why is it not a success story? Biotechnology inRussia:Whyisitnotasuccessstory? ROGER ROFFEY Biotechnology in Russia: Why is it not a success story? According to President Medvedev 2009 ‘By and large, our industry continues to make the same outdated products and, as a rule, imported generics from substances bought abroad. There is practically no work to create original medicines and technologies.’…‘We must begin the modernisation and technological upgrading of our entire industrial sector. I see this as a question of our country’s survival in the modern world’… ‘These are the key tasks for placing Russia on a new technological level and making it a global leader’. Many states including Russia see biotechnology and its commercialization as a key driver for their future growth. The biotechnology area is characterized by being a very knowledge-intensive activity where there is increasing global competition for know-how. Russia had a very good historical base of R&D and know- how in biotechnology from the previous Soviet military programme. There have been many attempts since 2000 to revive the Russian biotechnology industry not least in 2005 but without much success. In 2009 there were again very ambitious programmes and strategies developed as well as techno-parks for the ROGERROFFEY development of the biotechnology and pharmaceuticals industry up to 2020. It has also been announced by President Medvedev the creation of a Russian equivalent to ‘Silicon Valley’ to include R&D also in biotechnology outside Moscow. There have been many such grand plans but so far they have not been very successful and the question for this study was if it would be different this time? Why are scientists still leaving Russia and foreign investors still hesitating to invest in Russian biotechnology or pharmaceuticals? Why is Russia still not able to compete on the global biotechnology market and is ranked only as number 70 in the world? The current problems and prospects for the biotechnology and pharmaceuticals industries are analysed.
    [Show full text]
  • LIST of REGISTRED DRUGS in ARMENIA (Up to 31.12.2017)
    LIST OF REGISTRED DRUGS IN ARMENIA (Up to 31.12.2017) International nonproprietary Registration Term of Legal status for N Trade name name (generic) or Drug form Dose and packaging Manufacturer Country ATC1 code License holder number registration supply active ingredients name Lek Pharmaceuticals pefloxacin Lek Pharmaceuticals 400mg, 10.03.2015 d.d., Verovskova Str. 1 Abaktal (pefloxacin tablets film-coated d.d., Verovskova Str. Slovenia J01MA03 14308 PoM2 in blister (10/1x10/) 10.03.2020 57, 1526 Ljubljana, mesylate dihydrate) 57, 1526 Ljubljana Slovenia Lilly France S.A.S., Eli Lilly Regional 100IU/ml, Zone Industrielle, 2 17.03.2017 Operations GmbH., 2 Abasaglar insulin glargine solution for injection France A10AE04 16535 PoM 3ml cartridges (5) rue du Colonel Lilly, 17.03.2022 Koelblgasse 8-10, 67640 Fegersheim 1030, Vienna, Austria Help S.A ,10 ambroxol Help S.A. Pedini, Valaoritou str., GR 6mg/ml, 09.03.2016 3 Abrobion (ambroxol syrup Ioanninon, Ioannina, Greece R05CB06 15404 OTC3 144 52, 125ml glass bottle 09.03.2021 hydrochloride) 45500 Metamorphosis, Attika, Greece Salutas Pharma GmbH, Otto-von- Guericke-Alle-1, 100mg/5ml, 39179 Barleben-batch Sandoz 30g powder in 75ml glass powder for oral releaser, Allphamed Pharmaceuticals d.d., bottle and measuring 20.10.2015 4 ACC acetylcysteine solution with orange Pharbil Arzneimittel Germany R05CB01 14947 OTC Verovskova Str. 57, spoon 5ml, 60g powder in 20.10.2020 flavour GmbH Hildebrandstr. 1000 Ljubljana, 150ml glass bottle and 12, 37081 Gottingen, Slovenia measuring spoon 5ml Germany-bulk manufacturer, packager 1 Salutas Pharma GmbH, Otto-von- Guericke-Alle-1, 39179 Barleben - Sandoz batch releaser Pharmaceuticals d.d., 100mg, 21.11.2014 5 ACC 100 acetylcysteine tablets effervescent (Hermes Pharma Germany R05CB01 13967 OTC Verovskova Str.
    [Show full text]
  • PR-Bird Flu-CCX-[MASTER]
    Avian Flu D-125TM H5N1 It's not a matter of if... it's a matter of WHEN BELIEVED BY US EPA TO KILL AVIAN FLU D-125 is a US EPA-registered sanitizer, disinfectant and cleaner effective against several strains of the Avian Flu. The US EPA does not currently have any products that are regis- tered against the particular H5N1 strain of Avian Flu; however, the US EPA has indicated that they believe D-125 will prove effective against H5N1 once testing is completed. These products are available in an economical concentrate and ready-to-use spray and wipe formulation. Both the concentrate and the ready-to-use are US EPA-registered to kill an extraor- dinary range of 120 plus microbial organisms including all of the pan-demic human influenza strains of the 20th century including: Influenza A / Brazil Virus Influenza A / Victoria (H3N2) Virus Influenza A2-Asian Virus Influenza B Virus (Allen Strain) Influenza C Virus (Taylor Strain) D-125 is a registered tademark of Microgen Inc. Parainfluenza Type 1 In addition to being among a select group of products believed effective against H5N1 Avian Flu Virus, D-125 registered for use in and has specific instructions for disinfecting poultry houses as well as meat, poultry and food processing plants. Microgen Inc. D-125 is also registered for use on both hard, non-porous Clinton Square Executive Center surfaces and on porous surfaces. West Caldwell, NJ 07006 USA www.microgeninc.com With such versatility and efficacy D-125 is the ultimate choice 1-800-420-7522 or 973-575-9025 when disinfecting and sanitizing.
    [Show full text]
  • Live Attenuated Influenza Vaccines Against
    ccines & a V f V a o c l c i a n n a Larionova et al., J Vaccines Vaccin 2013, 4:8 r t u i o o n DOI: 10.4172/2157-7560.1000208 J Journal of Vaccines & Vaccination ISSN: 2157-7560 Research Article Open Access Live Attenuated Influenza Vaccines against Highly Pathogenic H5N1avian Influenza: Development and Preclinical Characterization Natalie Larionova1*, Irina Kiseleva1, Irina Isakova-Sivak1, Andrey Rekstin1, Irina Dubrovina1, Ekaterina Bazhenova1, Ted M Ross2, David Swayne3, Larisa Gubareva4, Vadim Tsvetnitsky5, Ekaterina Fedorova1, Elena Doroshenko1 and Larisa Rudenko1 1Institute of Experimental Medicine, St. Petersburg, Russia 2University of Pittsburgh, Pittsburgh, PA, USA 3Southeast Poultry Research Laboratory, Athens, GA, USA 4Centers for Disease Control and Prevention, Atlanta, GA, USA 5PATH (Program for Appropriate Technologies in Health), USA Abstract In this paper we describe the development and the outcomes of the preclinical studies of temperature-sensitive and cold-adapted candidates for live attenuated influenza vaccine (LAIV) based on highly pathogenic avian influenza viruses A/H5N1 with pandemic potential. The LAIV candidates were developed by methods of classical re- assortment between H2N2 Master Donor Virus for Russian LAIV and H5N1 viruses generated by reverse genetics for inactivated vaccine. These reverse genetically generated viruses were chosen as a source of H5 hemagglutinin and contained a modified protease cleavage site believed to be associated with high virulence. The progeny of re- assortment had 7:1 gene composition and were characterized by antigen specificity of the HA of the pandemic virus, a high growth rate in chicken embryos and their parameters of temperature sensitivity and cold adaptation confirmed preserved attenuation of the Master Donor Virus.
    [Show full text]
  • Фармакология Pharmacology
    МИНИСТЕРСТВО ЗДРАВООХРАНЕНИЯ РЕСПУБЛИКИ БЕЛАРУСЬ БЕЛОРУССКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ КАФЕДРА ФАРМАКОЛОГИИ ФАРМАКОЛОГИЯ PHARMACOLOGY Практикум для специальности «Лечебное дело» 5-е издание, переработанное Минск БГМУ 2020 2 УДК 615(076.5)(075.8)-054.6 ББК 52.81я73 Ф24 Рекомендовано Научно-методическим советом университета в качестве практикума 29.05.2020 г., протокол № 9 А в т о р ы: проф. Н. А. Бизунок, проф. Б. В. Дубовик, доц. Б. А. Волынец, доц. А. В. Волчек Р е ц е н з е н т ы: д-р мед. наук, проф. А. В. Хапалюк; д-р. мед. наук, проф. А. И. Волотовский Фармакология = Pharmacology : практикум для специальности «Лечебное дело» / Ф24 Н. А. Бизунок [и др.]. – 5-е изд., перераб. – Минск : БГМУ, 2020. – 156 с. ISBN 978-985-21-0643-6. Содержит методические рекомендации для подготовки к лабораторным занятиям по фармакологии и задания для самостоятельной работы студентов, обучающихся по специальности 1-79 01 01 «Лечебное дело». Первое издание вышло в 2016 году. Предназначен для студентов 3-го курса медицинского факультета иностранных учащихся, изучающих фармакологию на английском языке. УДК 615(076.5)(075.8)-054.6 ББК 52.81я73 ISBN 978-985-21-0643-6 © УО «Белорусский государственный медицинский университет», 2020 3 CONTENTS INTRODUCTION ............................................................................................................................................................. 4 GENERAL PRESCRIPTION ...........................................................................................................................................
    [Show full text]
  • WO 2019/094700 Al 16 May 2019 (16.05.2019) W 1P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2019/094700 Al 16 May 2019 (16.05.2019) W 1P O PCT (51) International Patent Classification: (72) Inventors: SANTOS, Michael; One Kendall Square, C07K 14/435 (2006.01) A01K 67/04 (2006.01) Building 200, Cambridge, Massachusetts 02139 (US). A01K 67/00 (2006.01) C07K 14/00 (2006.01) DELISLE, Scott; One Kendall Square, Building 200, Cam¬ A01K 67/033 (2006.01) bridge, Massachusetts 02139 (US). TWEED-KENT, Ailis; One Kendall Square, Building 200, Cambridge, Massa¬ (21) International Application Number: chusetts 02139 (US). EASTHON, Lindsey; One Kendall PCT/US20 18/059996 Square, Building 200, Cambridge, Massachusetts 02139 (22) International Filing Date: (US). PATTNI, Bhushan S.; 15 Evergreen Circle, Canton, 09 November 2018 (09. 11.2018) Massachusetts 02021 (US). (25) Filing Language: English (74) Agent: WARD, Donna T. et al; DT Ward, P.C., 142A Main Street, Groton, Massachusetts 01450 (US). (26) Publication Language: English (81) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of national protection available): AE, AG, AL, AM, 62/584,153 10 November 2017 (10. 11.2017) US AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 62/659,213 18 April 2018 (18.04.2018) US CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 62/659,209 18 April 2018 (18.04.2018) US DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 62/680,386 04 June 2018 (04.06.2018) US HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 62/680,371 04 June 2018 (04.06.2018) US KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (71) Applicant: COCOON BIOTECH INC.
    [Show full text]